aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Misses Expectations By $3.43 EPS

aTyr Pharma (NASDAQ:ATYR) posted its quarterly earnings data on Thursday. The company reported ($7.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43), FiscalAI reports. The company had revenue of $235.23 million during the quarter, compared to the consensus estimate of $2.50 million.

aTyr Pharma Price Performance

aTyr Pharma stock traded up $0.32 during midday trading on Friday, reaching $6.35. 66,192 shares of the company traded hands, compared to its average volume of 83,642. aTyr Pharma has a 12 month low of $4.07 and a 12 month high of $44.40. The business has a 50 day moving average of $11.68 and a two-hundred day moving average of $23.59. The firm has a market capitalization of $15.56 million, a price-to-earnings ratio of -0.29 and a beta of 1.04.

Analyst Ratings Changes

ATYR has been the topic of several recent analyst reports. Wall Street Zen raised shares of aTyr Pharma to a “hold” rating in a research report on Saturday, October 31st. Wells Fargo & Company lifted their target price on shares of aTyr Pharma from $1.00 to $4.00 and gave the stock an “equal weight” rating in a report on Friday. Royal Bank Of Canada dropped their target price on shares of aTyr Pharma to $6.00 and set a “sector perform” rating on the stock in a research note on Friday. Finally, Weiss Ratings downgraded shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.00.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.